POLO-LIKE KINASE 1 (PLK1) REGULATES IFN INDUCTION BY MAVS

Damien Vitour¹⁺, Stéphanie Dabo¹⁺, Malek Ahmadi Pour¹, Myriam Vilasco¹, Pierre-Olivier Vidalain², Yves Jacob³, Mariana Mezel-Lemoine², Suzanne Paz⁴, Meztli Arguello⁴, Rongtuan Lin⁴, Frédéric Tangy², John Hiscott⁴ and Eliane F. Meurs¹

From Institut Pasteur, Unit of Hepacivirus and Innate Immunity¹, Laboratory of Viral Genomics and Vaccination², Unit of Genetics, Papillomavirus and Human Cancer³, Paris, 75015, France and McGill University, Molecular Oncology Group⁴, Lady Davis Institute for Medical Research, Montreal, H3T 1E2 Canada. +These authors contributed equally to this work.

Running head: Control of innate immune response by PLK1

Address correspondence to : Eliane F. Meurs, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France

(33) 1 45 68 87 77. Fax :(33) 1 40 61 30 12. E-mail : eliane.meurs@pasteur.fr

mitochondria-bound adapter participates in IFN induction by recruitment of downstream partners such as members of the TRAF family, leading to activation of NF-κB, and the IRF3 pathways. A yeast two-hybrid search for MAVS interacting proteins yielded the Polo-box domain (PBD) of the mitotic Pololike kinase PLK1. We showed that PBD associates with two different domains of MAVS dependent and independent phosphorylation events. The phospho-dependent association requires the phosphopeptide binding ability of PBD. It takes place downstream of the Proline-rich domain of MAVS, within an STP motif, characteristic of the binding of PLK1 to its targets, where the central T234 residue is phosphorylated. Its phospho-independent association takes place at the C-terminus of MAVS. PLK1 strongly inhibits the ability of MAVS to activate the IRF3 and pathways and to induce IFN. Reciprocally, depletion of PLK1 can increase IFN induction in response to RIG-I/SeV or RIG-I /poly(I)-poly(C) treatments. This inhibition is dependent on the phospho-independent association of PBD at the C-terminus of MAVS where it disrupts the association of MAVS with its downstream partner TRAF3. IFN induction was strongly inhibited in cells arrested in G2/M by nocodazole, which provokes increased expression of endogenous PLK1. Interestingly, depletion of PLK1 from these nocodazole-treated cells, could restore, at least partially, IFN induction. Altogether, these data demonstrate a new function for PLK1 as a regulator of IFN induction and provide the basis for the development of inhibitors preventing PLK1/MAVS association in order to sustain innate immunity.

The cellular innate immune response is triggered by a variety of microbial pathogens as an essential mechanism to limit the initial spread of these infections and involves the production of

inflammatory cytokines and type I interferons (IFN α/β) (1). In the particular case of infections with RNA viruses, IFN- α/β induction occurs following interaction of viral RNAs with two CARD-containing DE/xDH helicases: RIG-I (Retinoic acid Induced Gene-I (2) or MDA-5 (Melanoma Differentiation Associated gene-5) (3,4). RIG-I is activated upon recognition of ssRNAs with uncapped 5' triphosphate ends, specific homopolymeric RNA motifs or short dsRNA. In contrast, activation of MDA5 occurs upon recognition of long dsRNA (5,6,7,8,9). Through their N-terminal CARD domains, both RIG-I and MDA5 activate the same downstream partner, the mitochondria-bound protein MAVS (also termed IPS-1, VISA, Cardif) (10-13). MAVS, in turn, activates the IKK $\alpha\beta\gamma$ complex and the TBK1/IKKE kinases, thus provoking activation of NF-κB and IRF3 transcription factors and, ultimately, IFN induction (14,15).

The association between MAVS and RIG-I appears to be directed through homotypic interactions between their respective N-terminal CARD domains (16,17). In contrast, the mechanisms involved in the association of MAVS with the downstream signaling pathways are more complex, since they require activation of several kinases such as $IKK\alpha$, $IKK\beta$, $IKK\varepsilon$, and TBK1. MAVS associates with FADD and RIP (10-13,18) and with proteins of the TRAF family, such as TRAF3 and TRAF6 (12,19). Recruitment of FADD, RIP1 and TRAF3 to MAVS has been recently shown to occur in complex with TANK (20). In turn, TANK interacts with NEMO (NF-κB Essential Modulator), which bridges the nuclear factor-κB and the IRF3 signaling pathways (21,22).

The two kinases TBK1 and IKK ϵ present strong homologies (14,15). They both phosphorylate IRF3 and can compensate each other for IFN induction in innate immune cells (23). Yet they differ in several aspects, among which is the privileged association of IKK ϵ with MAVS at the mitochondria upon viral infection (18,24,25).

A systematic search for MAVS and IKKεinteracting proteins in a yeast two-hybrid screen revealed that both MAVS and IKKE were interacting with the Polo-box domain (PBD) of the polo-like kinase PLK1. Here, we report the MAVS/PLK1 association. The IKKε/PLK1 association will be addressed in a separate study. belongs to the family of mitotic serine/threonine Polo-like kinases that play critical roles in centrosome maturation, progression through mitosis and the onset of cytokinesis (26). PLK1 overexpression is known to occur in tumors and it is considered as a negative prognostic marker of progression to cancer (27). PLK1 usually associates with its cognate partners in a phospho-dependent manner through a phosphopeptide binding motif present in its Polo-box domain (28,29,30). Here, we show that the Polo-box domain of PLK1 associates with two different domains of MAVS. While one of these associations requires a phosphorylation event and the phosphopeptide binding motif of PLK1, the second one is phosphorylation-independent. Importantly, this non phospho-specific mode of interaction between PLK1 and MAVS was able to strongly disrupt the association of MAVS with its downstream partner TRAF3 and to interfere with the IFN induction pathway. PLK1 thus represents a new negative regulator of the IFN induction pathway.

Experimental procedures

Reagents- Control (scrambled) siRNA and siRNA to PLK1 (nucleotides 1416 to 1438 (31) were synthesized by Dharmacon Research, Inc. (Lafayette, CO). Normal mouse IgG, anti-c-Myc (9E10) and anti-PLK1 (F-8) monoclonal antibodies (mAbs) were from Santa Cruz. The anti-MAVS polyclonal antibody was from ALEXIS. Anti-actin and anti-FLAG mAbs (M2) were from Sigma. Anti-V5 mAb was from Invitrogen and anti-HSP60 mAbs from BD. Aphidicolin, Nocodazole and poly(I)-poly(C) were from Sigma. Anti-IKKε were provided by John Hiscott.

Yeast two-hybrid analysis- ORFs corresponding to MAVS (nucleotide 1 to 1539) were fused in frame using the following primers: MAVS-Forward(5'GGGGACAACTTTGTACAAAAAG TTGGCATGCCGTTTGCTGAAGACAAGA), MAVS-Reverse

(5'GGGGACAACTTTGTACAAGAAAGTTGGT TATGAGGGCCTGTGGCATGG),

with the coding sequence of the DNA-binding domain of Gal4 using *in vitro* recombination (Gateway system, Invitrogen) as previously described (32). Then, the Gal4-DB-MAVS construct was transfected in AH109 yeast cells (Clontech) according to the manufacturer's procedure. The fusion protein did not induce

transactivation. In parallel, a commercial human spleen cDNA library cloned in the Gal4-AD pPC86 two-hybrid vector (Invitrogen) was transfected in the Y187 yeast cells (Clontech). A mating strategy was used for two-hybrid screening of the human spleen cDNA library (33). Positive colonies were selected from ~50 million diploids on synthetic medium missing histidine and supplemented with 10 mM 3-amino-triazole (Sigma-Aldrich). The positive colonies were submitted to three rounds of screening to avoid contamination by irrelevant DNA (34). Positive clones were analyzed by direct sequencing of PCR products obtained from yeast colonies. The cDNA from these clones was then recovered and inserted into pDON^R vector (Invitrogen) to allow subsequent cloning in Gateway compatible acceptor plasmids, engineered by Y. Jacob.

Plasmids- The plasmid encoding FLAG-IKKE was described previously (14,35). The pV5-IKKE was generated by restriction digestion from pFLAG-IKKε(WT) and subsequent subcloning in a pcDNA3.1(+)-V5 vector engineered in the laboratory. The pcDNA3.1(+) vector was from Invitrogen. The pcDNA3.0-c-Myc-MAVS (pMyc-MAVS) full length (FL), 1-157 (N), and 156-540 (C) were described in (18). The Myc-MAVS constructs 364-540, 470-540, 1-180, 1-230, 1-280, 1-330, 1-360, 1-508, 156-513, 180-513, 230-513, 280-513, 330-513, Δ 364-470, Δ 364-470(T234A), T234A, T234D, T234E, 1-513(T234A), 1-513(T234D), 1-513(T234E), 1-513(S233DT234D), 1-513(S222DS233DT234D), ST233/234AA, SS257/258AA were generated by site-directed mutagenesis. pDEST GST-MAVS1-360 and pDEST GST-MAVS1-360 T234A were prepared as follows: the MAVS 1-360 fragments (wild type or the threonine to alanine mutant) were amplified by PCR and cloned into pDEST27 Gateway mammalian expression vector (Invitrogen). The following PCR primers were used for the amplification of MAVS 1-360 wild type and mutant: forward 5°primer ggggacaactttgtacaaaaaagttggcatgCCGTTTGCTGA AGACAAGA-3' and reverse 5'ggggacaactttgtacaagaaagttggttaTGGCACCATGCC AGCACG-3'. The sequence of the PLK1 cDNA fragment recovered from the yeast positive colonies corresponded to its polo-box domain (PLK1 323-603 for interaction with MAVS). The full length Myc-PLK1 plasmid was obtained from Roy Golsteyn (36). pMyc-PLK1 T210D and T210V mutants were obtained by site-directed mutagenesis. cloned in pDON207^R Full-length PLK1, (Invitrogen), was inserted in frame 3' of a triple FLAG epitope sequence into a translation optimized pCINeo vector (Promega) using the Gateway cloning procedure (Invitrogen) to generate pFLAG-PLK1. The PLK1-PBD fragment recovered from the yeast screen and subcloned in pDON207^R was

inserted in the triple FLAG pCINeo vector or pEGFP-C1 modified vector using the Gateway cloning procedure. They are referred to as pFLAG-PLK1-PBD and pEGFP-PLK1-PBD. The full length sequence of MAVS was amplified from the pMyc-MAVS plasmid and cloned into the triple FLAG vector to generate pFLAG-MAVS. The pFLAG-PLK1 construct containing the mutation K82M was generated by site-directed mutagenesis. The PLK1-PBD constructs with the mutations H538A, L540M +/- W414F, were generated by site-directed mutagenesis on the pFLAG-PLK1-PBD plasmid. The PLK1-PBD sequence and the full length cDNA of MAVS were subcloned into the pM and pVP16 vectors (Clontech) respectively. The IFN-β firefly luciferase (IFN-β-pGL2) and β-Galactosidase (pRSV-βGal) reporter plasmids were described previously (35). pGal4/Luc and pCMV Renilla luciferase reporter plasmids were obtained from Y. Jacob. pGal4/Luc was engineered from basic pGL3 vector (Promega). The FLAG-TRAF3 plasmid was generated by cloning human TRAF3 by reverse transcriptase-PCR assay and insertion into the pcDNA3 FLAG vector (a gift from R. Lin). The pEF-BOS FLAG- RIG-I plasmid was described in (2).

Cells and virus- HEK 293T, Hela and MCF7 cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin (Invitrogen). Huh7 cells were cultured as described previously (35). HEK 293T were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer. Infection with Sendaï virus (a gift from D. Garcin and D. Kolakofsky (37)) was performed as in (35).

Reporter assays- For IFN-β luciferase reporter assays, 1.4×10^5 cells were transfected with 100 ng of IFN-β-pGL2 and 50 ng of pRSV-β Gal using Lipofectamine 2000 (Invitrogen). Indicated amounts of the PLK1 constructs were co-transfected with MAVS constructs, or empty vector. siRNAs targeting PLK1 (final concentration 50 nM) were transfected 24 h before transfection of different amounts of MAVS. Cells were incubated for 24-48 h and were mock treated or infected with Sendai virus. The reporter assays were performed as described in (35). Data are shown as the mean activity of luciferase activity (normalized to β Galactosidase activity) of triplicates ± SEM.

For Gal4 luciferase reporter assays, 1.4 x 10⁵ cells were transfected with 100 ng of Gal4-luc and 20 ng of pCMV-Renilla using Lipofectamine 2000 (Invitrogen). 400 ng of pM-PLK1-PBD, containing the DNA-binding domain of Gal4 fused in frame with the Polo-box domain of PLK1, 400 ng of pVP16-MAVS, containing the full length sequence of MAVS fused in frame with the transactivator VP16, were transfected individually or co-transfected. The reporter assays were performed as recommended by the manufacturer.

Data are shown as the mean normalized luciferase activity of triplicates ± SEM.

Immunoprecipitation and immunoblot analysis-Cells were washed once with PBS and scraped in lysis buffer A (50 mM Tris-HCl, pH 7.5, 140 mM NaCl, 5% glycerol, 1% CHAPS) or buffer B (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100) containing cocktails of phosphatase and protease inhibitors (Complete, Roche). During lambda-phosphatase treatment (5 U/mg protein extract; 30 min at 30°C), phosphatase inhibitors were omitted. The protein content was analyzed by immunoblot as described (35). Lysates were incubated at 4°C overnight with the appropriate antibodies and then in presence of A/G agarose beads (Santa Cruz) for 60 min. The beads were washed three times and the precipitated proteins were extracted using SDS-PAGE sample buffer at 95°C. Lysate and immunoprecipitated material were resolved by SDS-PAGE, transferred onto PVDF membrane (Bio-RAD) and probed with antibodies directed against fused tags followed by appropriate secondary reagents. Bound antibodies were detected using the ECL Plus Western Blotting Detection System (Amersham).

In vivo phosphorylation- HEK 293T cells, plated at 3 x 10⁶ cells/100 mm plate, were washed once in Phosphate-free Dulbecco's Modified Eagle Medium (Invitrogen) and incubated for 10 h in this medium containing 10% of FBS, previously dialysed against phosphate-buffer-saline (PBS), 800 µCi to 1 mCi of [32P] orthophosphoric acid (8500-9120 Ci (314-337TBq)/mMole; Perkin Elmer) and 20 µM MG132 (Sigma). After lysis in buffer A, protein extracts were submitted to immunoprecipitation with the appropriate antibodies. Following separation by SDS-PAGE, the proteins were transferred to a PVDF membrane and the presence of proteins in the complex was revealed by appropriate antibodies, while the phosphorylated proteins were revealed after exposure of the membrane to an intensifying screen followed by scanning on a PhosphorImager.

Real-time RT-PCR analysis- Total cellular RNA was extracted by acid-guanidium thiocyanatephenol chloroform using RNAble (Eurobio, Les Ulis, France) according to the manufacturer. The sequence of the primers used for the reverse transcription polymerase chain reaction (RT-PCR) of GAPDH, IFN-β and ISG56 were described in (38). The sequences of the IL8 primers used for RT-**PCR** are: IL8-forward 5°-AAGGGCCAAGAGAATATCCGAA-3'and IL8reverse 5'- ACTAGGGTTGCCAGATTTAACA-3'. The RT reactions were performed on 1 µg total RNA using oligo dT primers and AMV reverse transcriptase (Promega). Quantitative PCR was performed on a light cycler apparatus using SYBR Green, with 2 µl of the cDNA in a 10 µl reaction mixture containing 2 µl Light Cycler FastStart Plus DNA master SYBR Green kit (Roche) and 0.1 µM

of each primer. Standard curves were established using 10-fold serial dilutions of plasmids containing amplicons (GAPDH, IFN-β and ISG56) or purified PCR product (IL8). The measured amounts of each mRNA were normalized to the amounts of GAPDH mRNA. The amounts of RNA were expressed as number of copies/μg total.

RESULTS

Identification of the Polo-like kinase PLK1 as partner to MAVS. A high-throughput yeast twohybrid screen (32) was performed to search for MAVS-interacting proteins. We used a MAVS construct deprived of its transmembrane domain (MAVS 1-513) to favour nuclear localization and efficient interaction with the prey library. Out of 5 x 10' transformants obtained with a human spleen cDNA library, 27 positive colonies were identified when MAVS was used as a bait. The mitotic serine/threonine Polo-like kinase PLK1 (39) was found as a major partner for MAVS along with two members of the TNF-receptor associated factor family, TRAF2 and TRAF6. These data were thus in agreement with those obtained from a previous yeast two-hybrid screen using MAVS as bait (12). The sequence of the recovered PLK1 cDNA fragment (PLK1 aa 323-603) corresponds to its Polo-box domain (PBD). The interaction between MAVS and the PLK1-PBD was confirmed in human cells using a mammalian two-hybrid assay in which the PLK1-PBD sequence was fused in frame with the DNA-binding domain of Gal4, while the MAVS sequence was fused to the transactivator VP16. Co-transfection of both constructs provoked an 8x-fold transactivation of a Gal4-driven luciferase gene, thus showing the relevance of the interactions revealed by the yeast two-hybrid screen (Fig 1A). Transient transfection and coprecipitation assays next showed that MAVS could interact with PLK1-PBD, as well as full length PLK1 (Fig 1B).

Endogenous association of PLK1 with MAVS. Expression of PLK1 is known to be linked to the cell cycle (39). Therefore, to determine whether MAVS and PLK1 could associate at the endogenous level, we first established the kinetics of PLK1 and MAVS expression as a function of the cell cycle, in three different cell types -HEK 293T, Huh-7 (Fig 1C) and Hela cells (Suppl Fig 1) - after growth arrest at G1/S interphase by aphidicolin treatment (26) or double thymidine block. These data confirmed the dependence of PLK1 expression upon the cell cycle with higher expression 8 to 12 hrs after block release, corresponding to the G2/M phase of the cycle. The expression of MAVS does not vary much during the cell cycle and a concomitant high expression of both proteins can be observed at the peak of PLK1 expression (Fig 1C and Suppl Fig 1). We then demonstrated that MAVS and PLK1 can interact at the endogenous

level by using extracts from HEK 293T cells arrested at G2/M by nocodazole treatment as described (40). We also used the breast cancer cell line MCF7 (41) since PLK1 expression was reported to be constitutively elevated in tumor cells (42). In our experimental conditions, however, the MCF7 behaved as the 293T cells with regards to endogenous levels of PLK1 and treatment with nocodazole was still necessary to increase these levels. Immunoprecipitation of endogenous MAVS pulled-down endogenous PLK1 from nocodazoletreated 293T and MCF7 cells in which expression of PLK1 was increased (Figure 1D). Only a fraction of PLK1 could be pulled down by MAVS, which may reflect a competition between MAVS and the numerous (>600) PLK1 mitotic targets Interestingly, treatment of cells with poly(I)poly(C), which activates endogenous MAVS through the dsRNA/RNA helicase pathway (4,8), did not increase MAVS/PLK1 association (done with HEK293T cells; Figure 1D left). This indicates that the association between MAVS and PLK1 may take place independently of MAVS activation.

PLK1-PBD associates with two different domains of MAVS. PLK1 recruits several of its targets by using a phosphopeptide binding motif located in its Polobox domain. Through this motif, it can recognize phosphorylated threonine or serine residues, which have been previously phosphorylated by specific upstream kinases. This phosphopeptide binding ability of PLK1 is dependent on three residues His538, Lys540 and Trp-414 (28,29,30). To determine the specificity of the association of PLK1 with MAVS, we generated the PLK1-PBD double mutant H538A/K540M and the PLK1-PBD triple mutant (PLK1-PBD W414F/H538A/K540M or PLK1-PBD M) and examined their ability to bind MAVS. Association of MAVS to both PLK1-PBD H538A/K540M and PLK1-PBD M mutants was reduced but still present, which suggested that the PLK1/MAVS association could be complex (Fig 2A). By generating different MAVS deletion constructs, we found that PLK1-PBD binds MAVS at two different domains: an N-terminal 1-280 domain and a C-terminal 364-540 domain (Fig 2B and C). The MAVS N-terminal domain associates to the PLK1-PBD construct phosphopeptide binding ability. Comparison of the efficiency of binding of PLK1-PBD to different MAVS fragments then allowed us to restrict this region of MAVS to a deduced amino acid sequence encompassing the residues 180 to 280 (Fig 2B). On the other hand, the MAVS C-terminal 364-540 domain binds PLK1-PBD, regardless of the mutations in the W414, H538A and K540 residues. With regards to this latter interaction, we could restrict it to the MAVS 364-470 region (Fig 2B). Two interesting observations provided more insights on this type of interaction. First, the MAVS constructs deleted of their transmembrane domain

(514-540) and lacking up to the first 230 residues (MAVS 230-513, 280-513 and 330-513) were unable to bind PLK1-PBD M, although they contain the 364-470 domain. This indicates that binding of PLK1 to the C-terminal domain of MAVS depends on the transmembrane domain of MAVS and, probably, on the localization of MAVS at the mitochondria. Second, PLK1-PBD M does not bind to a MAVS 155-540 construct despite of the presence of both the 364-470 domain and the transmembrane domain. Only PLK1-PBD can bind this construct, in accord with its ability to specifically recognize the MAVS 180-280 domain. This suggests that, in the absence of its first 155 residues, MAVS 156-540 may adopt a conformation that does not allow PLK1-PBD M to have access to the 364-470 domain. Altogether, these results reveal that PLK1 uses its Polo-box domain to associate with two distinct domains of MAVS of approximately 100 residues each, one near the Proline rich region of MAVS (180-280 aa) and one at the C-terminal domain of MAVS (367-470 aa) (summarized in Fig 2C).

Association of MAVS with the Polo- box domain of PLK1 depends on phosphorylation. We next examined the dependence of MAVS phosphorylation on its interaction with PLK1. For this, we generated two MAVS constructs: MAVS 1-360 and MAVS 360-540, each containing one of the PLK1-interaction domains. These constructs were expressed in HEK 293T cells in the presence of PLK1 full-length (FL) or PLK1-PBD and the cell extracts were treated with λ phosphatase prior to MAVS immunoprecipitation. The results show that the association of MAVS 1-360 or MAVS FL with PLK1 or PLK1-PBD was strongly inhibited by the phosphatase treatment. In contrast, association of the PLK1 constructs with MAVS 360-540 was unaffected (Fig 3). These data show that PLK1 associates with two separate domains of MAVS, one which depends on the phosphopeptide binding site of PLK1 and on a phosphorylation event, and one which is independent of both.

The serine 233 and threonine 234 residues of MAVS are required for its association with the phosphopeptide binding motif of PLK1-PBD. We have shown that the PBD of PLK1 associates specifically to the 180-280 domain of MAVS (Fig 2B). This domain contains several threonine and serine residues that could serve as phosphorylation sites (suppl Fig 2). In particular, its P₂₂₉₋L₋A₋R₋S₋T₋ P₂₃₅ motif resembles the PLK1 phosphopeptide binding consensus motif $[P/F]-[\Phi/P]-[\Phi/A/Q]-$ [T/Q/H/M]-S-[pT/pS]-[P/X] (29). Introduction of the ST_{233/234}AA substitution into full length MAVS or MAVS 156-540 strongly reduced their ability to PLK1-PBD, whereas the substitution SS_{257/258}AA had no effect (Fig 4A; lanes 3 and 6 as compared to lanes 4 and 7). The remaining association depicted in lanes 3 and 6 is likely due to

PLK1 interaction with the C-terminal domain of MAVS. Accordingly, the MAVS 1-513 construct, which lost its ability to bind PLK1 through its Cterminus, became unable to bind PLK1 when bearing the ST_{233/234}AA substitution (Fig 4A; lanes 9 and 10). Phosphorylation of the threonine residue within the motif STP has been previously shown to be required for the binding of the Polo-box domain, while the serine residue that precedes the phosphorylated T makes three hydrogen-bond interactions with PBD, through water molecules (29). MAVS constructs bearing the single T₂₃₄A or S₂₃₃A substitution were found to have a strongly reduced ability to bind PLK1-PBD (Fig 4B and Suppl. Fig 3). However, substitution of the T_{234} residue to the phosphomimetic aspartic (D) or glutamic (E) acid residues could not restore the ability of PLK1-PBD to bind MAVS full length or MAVS 1-513 (Fig 4B). It is possible that the D/E substitution is not able to act as a phosphomimetic and that authentic phosphorylation of T_{234} is recognition by PLK1-PBD. necessary for Altogether, these results clearly show that the S₂₃₃ and T₂₃₄ residues of MAVS play an important role in the recruitment of PLK1 to MAVS.

In vivo phosphorylation of MAVS. Since PLK1 uses its phosphopeptide binding ability to bind MAVS, we set out to determine whether MAVS could be phosphorylated in vivo. We performed MAVS immunoprecipitation experiments after in vivo [32P] labelling of cells expressing MAVS FL, or the MAVS 1-360 or MAVS 360-540 fragments. Expression of each of these constructs was performed alone or in the presence of Flag-PLK1 since PLK1 has been reported to phosphorylate some of its docking targets (43). As a control for phosphorylation, we used V5-IKKE since we have observed that this kinase can phosphorylate MAVS (25). The results show that MAVS full length was constitutively phosphorylated and that its phosphorylation was increased in the presence of IKKε (Fig 4C). MAVS 1-360 was also constitutively phosphorylated whereas MAVS 360-540 was not. Neither IKKε nor PLK1 could increase the phosphorylation of MAVS 1-360. MAVS 360-540 was not phosphorylated in the presence of PLK1 but became strongly phosphorylated in the presence of IKKε (Fig 4C). The ability of IKKE to phosphorylate the Cterminus of MAVS was beyond the scope of this investigation and will be addressed in a separate study. Finally, we compared the in vivo phosphorylation state of different concentrations of MAVS 1-360 constructs that differ only by the presence of a threonine or an alanine residue at position 234. We have verified that the former binds PLK1-PBD and the other not (supplemental figure 3A). The results show a strong and specific increase in the phosphorylation state of MAVS1-360 expressing authentic T234, therefore indicating

the importance of this residue in MAVS phosphorylation (Fig 4D). Altogether, these results show for the first time that MAVS can be phosphorylated in vivo. In particular, the phosphorylation of the threonine 234 residue at the N-terminal domain of MAVS can provide the physiological conditions necessary to recruit PLK1 through the phosphopeptide binding motif.

inhibits MAVS-mediated IFNβ PLKIstimulation. MAVS is an important factor of the IFN inducing pathway. We, therefore, examined the effect of PLK1 on MAVS activity, using functional reporter assays (Fig 5A). PLK1 alone had no intrinsic ability to induce IFN, in agreement with a previous report (12). However, when expressed in the presence of MAVS, PLK1 strongly inhibited the stimulation of the IFNβ promoter (60%), as well as the induction of the endogenous ISG56 (50%) and IL-8 (80%) genes, used as representatives of the IRF-3 and NF-κB signalling pathways, respectively (Fig 5A). The effect of PLK1 on the IFN inducing pathway was then examined in response to infection by Sendaï virus (SeV), one of the viruses activating the RIG-I/MAVS pathway (5). A 75-fold stimulation of the IFN_β promoter provoked by the SeV infection was strongly inhibited in the presence of overexpressed PLK1 (84%) (Fig 5B left). A similar inhibition was observed on endogenous IFNβ induced by SeV (Fig 5B right).

We used MAVS mutants containing the T₂₃₄A substitution and/or a deletion of the 364-470 domain to determine the relative importance of the two PLK1-binding domains on PLK1-mediated inhibition of MAVS. MAVS FL and the MAVS constructs MAVS $T_{234}A$, MAVS $\Delta 364-470$ and the double mutant MAVS $T_{234A}\Delta 364-470$ were expressed in the presence of PLK1 or PLK1-PBD and assessed for their ability to induce an IFNB reporter vector (Fig 5C top). In parallel, these constructs were assayed for their ability to bind PLK1 or PLK1-PBD (Fig 5C bottom). The results confirmed efficient binding of both PLK1 and PLK1-PBD to MAVS FL (see Figs 1, 2 and 4) and inhibition of MAVS activity by PLK1 (see Fig 5A and B). In addition, these results show that PLK1-PBD is just as efficient as PLK1 FL in inhibiting the activity of MAVS FL (Fig 5C top). PLK1 failed to bind MAVS $T_{234}A$ and MAVS $T_{234}A\Delta 364-470$ and lost most of its ability to inhibit the activity of these MAVS constructs. In contrast, PLK1 was still efficient in binding MAVSΔ364-470 and could inhibit its activity. PLK1-PBD could bind MAVS T₂₃₄A with reduced efficacy as compared to MAVS FL and was able to inhibit MAVS activity. PLK1-PBD was able also to bind MAVSΔ364-470 as efficiently as MAVS FL but could not inhibit it. Finally, PLK1-PBD was able to only poorly bind to MAVS $T_{234}A\Delta 364-470$ and was not able to inhibit its IFN inducing ability. Altogether, these results show that both PLK1-binding domains of MAVS

are involved in the inhibition of MAVS by PLK1. A possible scenario of the MAVS/PLK1 interaction and effect on IFN induction is presented in the discussion (see also Fig 8). The ability of PLK1 to inhibit the IFN induction pathway was further strengthened by the fact that depletion of endogenous PLK1 by siRNA resulted in an increase in MAVS activity (Fig 5D). Finally, we analyzed the effect of the depletion of PLK1 on the RIG-I signaling pathway by transfecting limited amounts of RIG-I and analyzing stimulation of the IFN signaling pathway 6 hours after infection with Sendaï virus. The results show that in conditions where the viral infection strongly activates RIG-I and IFN induction, depletion of PLK1 further potentiates this signaling pathway (Fig 5E).

PLK1 inhibits IFN induction by disrupting the TRAF3/MAVS association. MAVS activity has been reported to depend on its association with members of the TRAF family, such as the E3-ubiquitin ligases TRAF2, TRAF6 and TRAF3 through TRAF interacting motifs (TIM). In particular, TRAF3 is involved in the activation of the IRF3 pathway, which is essential for IFN induction (19). We thus determined the effect of PLK1-PBD on the MAVS/TRAF3 association. As a control, we compared it to the known association between MAVS and IKKE (18,25). We performed coprecipitation studies of MAVS and TRAF3 in the presence of increasing amounts of PLK1-PBD. Increasing PLK1-PBD led to a strong reduction of the MAVS/TRAF3 association, whereas this had no effect on the MAVS/IKKE association (Fig 6A). Recent reports show that MAVS dimerization leads to recruitment of downstream partners (44,45). We showed that PLK1 was unable to prevent MAVS dimerization (Supplem Figure 4), thus indicating that PLK1 can bind MAVS regardless of its state of activation. This is in accord with the data in figure 1 where we showed that binding of PLK1 to MAVS was not increased in the presence of poly(I)poly(C). We then analyzed the effect of increasing concentrations of PLK1-PBD on the association of TRAF3 with the two MAVS 1-360 and 360-540 constructs, each containing one of the PLK1binding domains. First, we found that TRAF3 associates with MAVS 360-540 and not with MAVS 1-360 (S. Paz, M. Vilasco, M. Arguello unpublished observation) in contrast with the data from Saha et al (19). The difference between our results and those of Saha et al. may be related to the MAVS constructs used in each case. The role of the C-terminal TRAF3 binding domain of MAVS will be addressed in a separate study. Interestingly, PLK1-PBD was able to strongly abolish the interaction of TRAF3 to the MAVS 360-540 domain (Fig 6B). This was in accord with our functional reporter assay in which deletion of MAVS 364-470 restores MAVS activity in presence of PLK1-PBD. These data demonstrate that one

possible mechanism for the negative regulation of PLK1 in IFN induction is through the interaction of its PBD at the C-terminal domain of MAVS and involves deregulation of TRAF3.

PLK1 participates in the inhibition of IFN induction during treatment with antimicrotubule drugs. Since nocodazole treatment allows to detect PLK1/MAVS interaction (Figure 1D), we were prompted to examine whether nocodazole could affect the MAVS-mediated innate immune response alone or in the presence of PLK1. To test this, HEK 293T cells, depleted or not from their endogenous PLK1, were submitted to nocodazole treatment and MAVS signaling was assayed after transfection with RIG-I and poly(I)-poly(C). The results first confirmed that depletion of PLK1 can increase the RIG-I-mediated IFN induction as shown in figure 5E where SeV was used as an activator for RIG-I. Here, poly(I)poly(C) was used instead of SeV due to the concern that endocytosis of the virus might be impaired by the depolymerization of the microtubules upon nocodazole treatment. In those conditions, we observed that nocodazole treatment strongly increased the expression levels of PLK1 and led to a dramatic inhibition of IFN induction. Interestingly, depletion of PLK1 was found to partially restore IFN induction (Fig 7). These data suggest that anticancer treatments using agents interfering with the dynamics of microtubules may provoke an unwanted increase in PLK1 that can interfere with the innate immune signaling pathways.

DISCUSSION

A search for partners to the IFN-inducing mitochondrial adapter MAVS by a yeast two-hybrid assay revealed the mitotic Polo-like kinase PLK1. We show that PLK1 interacts with MAVS through its Polo-box domain and interferes with induction of IFN.

One of the particularities of PLK1 is to bind its targets through its Polo-Box domain, in a phospho-dependent manner, via a pSer/pThrbinding module that specifically recognizes Ser-[pSer/pThr]-Pro/X motifs and favors localization of PLK1 to specific subcellular structures (46). More that 600 potential targets for PLK1 have already been identified by affinity purification and mass spectrometry studies (40). Here, we showed that MAVS behaves as a target for PLK1 based on the fact that full association of MAVS with PLK1 requires the phosphopeptide binding motif of PLK1 (Fig 2) and based on in vivo phosphorylation events (Fig 3). We could link this specific association to the N- terminal end of MAVS, between residues 180 and 280 (Fig 2). This region contains an S₂₃₃T₂₃₄P motif that could correspond to the phosphopeptide Ser-[pSer/pThr]-Pro recognized by PBD (29,40) and indeed, we showed the importance of both MAVS residues S233 and T234 in

its association with PLK1 since their substitution to alanine impairs the association (Fig 4A). Substitution of T_{234} or S_{233} to the phosphomimetics D/E could not restore association of MAVS to PLK1-PBD (Fig 4B and Suppl Fig3). This indicates that the authentic presence of a phosphate may be essential for MAVS to behave as a target for PLK1. Indeed, our experimental data showed that MAVS can be phosphorylated in vivo on its 1-360 domain and that the substitution T234A decreased its level of phosphorylation (Fig 4D). We have observed that the phosphorylation of MAVS 1-360 was not increased in the presence of PLK1. Priming kinases responsible for the phosphorylation of MAVS at its PLK1 binding-STP motif are currently being searched.

We found that PLK1 was also able to bind to the C-terminal domain of MAVS, irrespective of its phosphopeptide binding ability (Fig 2) and in a phospho-independent manner (Fig 3). This may involve direct binding of this MAVS domain to a different interface of PLK1-PBD or may involve other partner(s) related to the localization of MAVS at the mitochondria. Recently, a phosphorylation-independent binding of PLK1-PBD to the protein Bora has also been reported (47).

In view of the importance of MAVS in IFN induction, we examined the effect of PLK1 on this signaling pathway. PLK1 behaved as a strong inhibitor of the MAVS-mediated ability to induce IFN through the downstream NF-κB and IRF3 signalling pathways. PLK1 was also able to inhibit IFN induction in response to a viral stimulus, such as Sendaï virus and silencing of its expression could boost IFN induction in response to MAVS. MAVS mutated in its N-terminal PLK1 binding domain no longer binds PLK1 and is resistant to its inhibition. MAVS mutated in its C-terminal PLK1 binding domain still binds PLK1. These results indicate that the recruitment of PLK1 to the N-terminal domain of MAVS through its phosphopeptide docking site may occur first. Then PLK1 would bind the Cterminus of MAVS through a different surface on its PBD (Fig 5C). This would interfere with the recruitment of TRAF3 and subsequently inhibit MAVS activity. A temptative model of the PLK1/MAVS association is presented in Fig 8.

As expected from its negative role on MAVS activity, silencing of PLK1 was able to increase induction of IFN in response to ectopically expressed MAVS (Fig 5D). In this respect, PLK1 belongs to the list of recently reported regulators of the IFN induction pathway at the level or immediately downstream of MAVS. For instance, the RNA helicase LGP2, similar to RIG-I and MDA5, but devoid of the CARD-like domain, binds a region close to the C-terminal domain of MAVS and can interfere with the binding of IKK ϵ (16). NLRX1, a nucleotide-binding domain (NBD)- and leucine-rich-repeat (LRR)-containing family

member (NLR) localizes to the mitochondrial outer membrane, interacts with MAVS and inhibits MAVS activity (48). Deubiquitinating enzyme A (DUBA), an ovarian tumor domain-containing deubiquitinating enzyme, binds to and selectively cleaves the lysine-63-linked polyubiquitin chains on TRAF3 resulting in its dissociation from the downstream signaling complex containing TBK1 and behaves as a negative regulator of innate immune responses (49).

Silencing of PLK1 was found to increase MAVS activity, while its overexpression inhibited MAVS. PLK1 expression levels vary during the cell cycle. In the course of our study, we have shown that nocodazole treatment, which can increase the expression levels of PLK1 and favour its association with MAVS, can also strongly inhibit IFN induction. Depletion of PLK1 could partially restore IFN induction, confirming that at the endogenous level, PLK1 plays a role in the control of innate immunity. Nocodazole treatment is known to interfere with the polymerization of microtubules. PLK1 interacts through its kinase domain to all three components of microtubules, α -tubulin, β tubulin and γ-tubulin, regardless of their association in microtubules or not (50). It has been recently shown that mitochondria can move along the microtubule network (51). One attracting hypothesis is that, once bound to microtubules through its kinase domain, PLK1 may interact with MAVS through its Polo-box domain and control MAVS activity.

overexpression characterized in many tumor cells as a marker of tumor progression (42). Several examples indicate a correlation between the dysregulation of PLK1 expression and/or activity during infection with some viruses that are known to provoke uncontrolled cell proliferation and drive the cells toward cancer. For example, CD4(+) T cells from SIV-infected rhesus macaques with high viral loads exhibited both upregulation of Plk1 and an aberrant activation-induced Plk1 response, indicating that SIV-related disease may contribute to aberrant Tcell responses and disease pathogenesis (52). Interestingly, in the case of HIV infection, Vpr can increase viral replication, arrest proliferating CD4+ T cells in the G2 phase of the cell cycle, and provoke cell division defects in fission yeast, Hela and primary cells. In particular, it was shown to provoke mislocalization of the Plo1 yeast homolog

of Polo kinase, resulting in multiple discrete cytoplasmic dots or concentration in the nucleus (53). The hypothesis that a reorganisation of PLK1 during HIV-I infection may favour its association with MAVS and control of innate immune response remains to be explored. The human papillomavirus type-16 E6/E7 proteins also provoked the deregulation of cellular genes such as Plk1, Aurora-A, cdk1, and Nek2, thus contributing to genomic instability and conversion to cancer cells, in addition to abrogating the normal functions of p53 and retinoblastoma (54).

Our results show an association between PLK1 and the C-terminal domain of MAVS and its control on MAVS activity. These data support the new notion that one of the aspects of the ability of PLK1 to drive the cells towards tumorigenesis is its ability to deregulate the innate immune control of the cells. We have shown that treatment of cells with anti-microtubule agents, such as nocodazole, can dramatically inhibit IFN induction but that some restoration of IFN induction could be achieved by depleting PLK1 from the cells. It has been recently reported that the treatment of breast cancer with siRNAs targeting PLK1 improved the sensitivity toward paclitaxel and induced an antiproliferative effect (55). It is possible that depleting PLK1 would prevent its negative control of MAVS and allow sufficient induction of IFN, which also has antiproliferative action. In addition to siRNA aimed at depleting PLK1 in tumoral cells, other strategies are aimed to inhibit the kinase activity of PLK1 through chemical inhibitors, such as the ATPcompetitive dihydropteridinone derivative BI2536, (42,56). The clinical potential of inhibitors that target the Polo-box domain in order to prevent access of PLK1 to its cellular partners is also being investigated. In this respect, the synthetic thymoquinone derivative Poloxin has been shown to cause PLK1 mislocalization, mitotic arrest and apoptosis in HeLa cells (57). Here, we have shown for the first time that the PLK1 inhibits IFN induction at the level of MAVS through its polobox domain. Specific inhibitors that prevent binding of PLK1 to MAVS would therefore be of great interest for therapeutic intervention in viro-induced cancers, in conjunction with the use of antimicrotubules agents, in order to strengthen the ability of the cells to mount an innate immune response.

REFERENCES

- 1. Barton, G. M., and Medzhitov, R. (2003) *Science* **300**(5625), 1524-1525
- 2. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., and Fujita, T. (2004) *Nat Immunol* **5**(7), 730-737
- 3. Kang, D. C., Gopalkrishnan, R. V., Wu, Q., Jankowsky, E., Pyle, A. M., and Fisher, P. B. (2002) *Proc Natl Acad Sci U S A* **99**(2), 637-642
- 4. Andrejeva, J., Childs, K. S., Young, D. F., Carlos, T. S., Stock, N., Goodbourn, S., and Randall, R. E. (2004) *Proc Natl Acad Sci U S A* **101**(49), 17264-17269
- 5. Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K. K., Schlee, M., Endres, S., and Hartmann, G. (2006) *Science* **314**(5801), 994-997
- 6. Pichlmair, A., Schulz, O., Tan, C. P., Naslund, T. I., Liljestrom, P., Weber, F., and Reis e Sousa, C. (2006) *Science* **314**(5801), 997-1001
- Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J., and Gale, M., Jr. (2008) Nature 454(7203), 523-527
- 8. Kato, H., Takeuchi, O., Mikamo-Satoh, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., Dermody, T. S., Fujita, T., and Akira, S. (2008) *J Exp Med* **205**(7), 1601-1610
- 9. Saito, T., and Gale, M., Jr. (2008) J Exp Med 205(7), 1523-1527
- 10. Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K. J., Takeuchi, O., and Akira, S. (2005) *Nat Immunol* **6**(10), 981-988
- 11. Seth, R. B., Sun, L., Ea, C. K., and Chen, Z. J. (2005) Cell 122, 1-14
- 12. Xu, L. G., Wang, Y.-Y., Han, K.-J., Lii, L.-Y., Zhai, Z., and Shu, H.-B. (2005) *Molecular Cell* 19, 1-14
- 13. Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., and Tschopp, J. (2005) *Nature* **437**(7062), 1167-1172
- 14. Sharma, S., tenOever, B. R., Grandvaux, N., Zhou, G. P., Lin, R., and Hiscott, J. (2003) *Science* **300**(5622), 1148-1151
- 15. Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S. M., and Maniatis, T. (2003) *Nat Immunol* 4(5), 491-496
- 16. Saito, T., Hirai, R., Loo, Y. M., Owen, D., Johnson, C. L., Sinha, S. C., Akira, S., Fujita, T., and Gale, M., Jr. (2007) *Proc Natl Acad Sci U S A* **104**(2), 582-587
- 17. Vitour, D., and Meurs, E. F. (2007) *Sci STKE* **2007**(384), pe20
- 18. Lin, R., Lacoste, J., Nakhaei, P., Sun, Q., Yang, L., Paz, S., Wilkinson, P., Julkunen, I., Vitour, D., Meurs, E., and Hiscott, J. (2006) *J Virol* **80**(12), 6072-6083
- 19. Saha, S. K., Pietras, E. M., He, J. Q., Kang, J. R., Liu, S. Y., Oganesyan, G., Shahangian, A., Zarnegar, B., Shiba, T. L., Wang, Y., and Cheng, G. (2006) *Embo J* **25**(14), 3257-3263
- 20. Michallet, M. C., Meylan, E., Ermolaeva, M. A., Vazquez, J., Rebsamen, M., Curran, J., Poeck, H., Bscheider, M., Hartmann, G., Konig, M., Kalinke, U., Pasparakis, M., and Tschopp, J. (2008) *Immunity* **28**(5), 651-661
- 21. Zhao, T., Yang, L., Sun, Q., Arguello, M., Ballard, D. W., Hiscott, J., and Lin, R. (2007) Nat Immunol
- 22. Pomerantz, J. L., and Baltimore, D. (1999) EMBO J. 18(6694-6704
- 23. Matsui, K., Kumagai, Y., Kato, H., Sato, S., Kawagoe, T., Uematsu, S., Takeuchi, O., and Akira, S. (2006) *J Immunol* 177(9), 5785-5789
- 24. Komuro, A., and Horvath, C. M. (2006) *J Virol* **80**(24), 12332-12342
- 25. Paz, S., Vilasco, M., Arguello, M., Sun, Q., Lacoste, J., Nguyen, T. L., Zhao, T., Shestakova, E. A., Zaari, S., Bibeau-Poirier, A., Servant, M. J., Lin, R., Meurs, E. F., and Hiscott, J. (2009) *Mol Cell Biol* **29**(12), 3401-3412
- 26. Gumireddy, K., Reddy, M. V., Cosenza, S. C., Boominathan, R., Baker, S. J., Papathi, N., Jiang, J., Holland, J., and Reddy, E. P. (2005) *Cancer Cell* **7**(3), 275-286
- 27. Reagan-Shaw, S., and Ahmad, N. (2005) Faseb J 19(6), 611-613
- 28. Cheng, K. Y., Lowe, E. D., Sinclair, J., Nigg, E. A., and Johnson, L. N. (2003) *Embo J* **22**(21), 5757-5768
- 29. Elia, A. E., Rellos, P., Haire, L. F., Chao, J. W., Ivins, F. J., Hoepker, K., Mohammad, D., Cantley, L. C., Smerdon, S. J., and Yaffe, M. B. (2003) *Cell* **115**(1), 83-95
- 30. Garcia-Alvarez, B., de Carcer, G., Ibanez, S., Bragado-Nilsson, E., and Montoya, G. (2007) *Proc Natl Acad Sci U S A* **104**(9), 3107-3112
- 31. Spankuch-Schmitt, B., Wolf, G., Solbach, C., Loibl, S., Knecht, R., Stegmuller, M., von Minckwitz, G., Kaufmann, M., and Strebhardt, K. (2002) *Oncogene* **21**(20), 3162-3171

- 32. Walhout, A. J. M., Sordella, R., Lu, X. W., Hartley, J. L., Temple, G. F., Brasch, M. A., Thierry-Mieg, N., and Vidal, M. (2000) *Science* **287**(5450), 116-122
- 33. Fromont-Racine, M., Rain, J. C., and Legrain, P. (1997) Nat Genet 16(3), 277-282
- 34. Vidalain, P. O., Boxem, M., Ge, H., Li, S., and Vidal, M. (2004) Methods 32(4), 363-370
- 35. Breiman, A., Grandvaux, N., Lin, R., Ottone, C., Akira, S., Yoneyama, M., Fujita, T., Hiscott, J., and Meurs, E. F. (2005) *J Virol* **79**(7), 3969-3978
- 36. Golsteyn, R. M., Schultz, S. J., Bartek, J., Ziemiecki, A., Ried, T., and Nigg, E. A. (1994) *J Cell Sci* **107 (Pt 6)**, 1509-1517
- 37. Strahle, L., Garcin, D., and Kolakofsky, D. (2006) Virology 351(1), 101-111
- 38. Vilasco, M., Larrea, E., Vitour, D., Dabo, S., Breiman, A., Regnault, B., Riezu, J. I., Eid, P., Prieto, J., and Meurs, E. F. (2006) *Hepatology* **44**(6), 1635-1647
- 39. Barr, F. A., Sillje, H. H., and Nigg, E. A. (2004) Nat Rev Mol Cell Biol 5(6), 429-440
- 40. Lowery, D. M., Clauser, K. R., Hjerrild, M., Lim, D., Alexander, J., Kishi, K., Ong, S. E., Gammeltoft, S., Carr, S. A., and Yaffe, M. B. (2007) *Embo J* **26**(9), 2262-2273
- 41. Dickson, R. B., Bates, S. E., McManaway, M. E., and Lippman, M. E. (1986) *Cancer Res* **46**(4 Pt 1), 1707-1713
- 42. Strebhardt, K., and Ullrich, A. (2006) *Nat Rev Cancer* **6**(4), 321-330
- 43. Neef, R., Gruneberg, U., Kopajtich, R., Li, X., Nigg, E. A., Sillje, H., and Barr, F. A. (2007) *Nat Cell Biol* **9**(4), 436-444
- 44. Baril, M., Racine, M. E., Penin, F., and Lamarre, D. (2009) J Virol 83(3), 1299-1311
- 45. Tang, E. D., and Wang, C. Y. (2009) *J Virol* **83**(8), 3420-3428
- 46. Elia, A. E., Cantley, L. C., and Yaffe, M. B. (2003) Science 299(5610), 1228-1231
- 47. Seki, A., Coppinger, J. A., Du, H., Jang, C. Y., Yates, J. R., 3rd, and Fang, G. (2008) *J Cell Biol* **181**(1), 65-78
- 48. Moore, C. B., Bergstralh, D. T., Duncan, J. A., Lei, Y., Morrison, T. E., Zimmermann, A. G., Accavitti-Loper, M. A., Madden, V. J., Sun, L., Ye, Z., Lich, J. D., Heise, M. T., Chen, Z., and Ting, J. P. (2008) *Nature* **451**(7178), 573-577
- 49. Kayagaki, N., Phung, Q., Chan, S., Chaudhari, R., Quan, C., O'Rourke, K. M., Eby, M., Pietras, E., Cheng, G., Bazan, J. F., Zhang, Z., Arnott, D., and Dixit, V. M. (2007) *Science* **318**(5856), 1628-1632
- 50. Feng, Y., Hodge, D. R., Palmieri, G., Chase, D. L., Longo, D. L., and Ferris, D. K. (1999) *Biochem J* **339 (Pt 2)**, 435-442
- 51. Huang, B., Jones, S. A., Brandenburg, B., and Zhuang, X. (2008) *Nature methods* **5**(12), 1047-1052
- 52. Bostik, P., Dodd, G. L., Villinger, F., Mayne, A. E., and Ansari, A. A. (2004) *J Virol* **78**(3), 1464-1472
- 53. Chang, F., Re, F., Sebastian, S., Sazer, S., and Luban, J. (2004) *Mol Biol Cell* **15**(4), 1793-1801
- 54. Patel, D., Incassati, A., Wang, N., and McCance, D. J. (2004) Cancer Res 64(4), 1299-1306
- 55. Spankuch, B., Kurunci-Csacsko, E., Kaufmann, M., and Strebhardt, K. (2007) *Oncogene* **26**(39), 5793-5807
- 56. Steegmaier, M., Hoffmann, M., Baum, A., Lenart, P., Petronczki, M., Krssak, M., Gurtler, U., Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G. R., Kraut, N., Peters, J. M., and Rettig, W. J. (2007) *Curr Biol* 17(4), 316-322
- 57. Reindl, W., Yuan, J., Kramer, A., Strebhardt, K., and Berg, T. (2008) Chem Biol 15(5), 459-466

FOOTNOTES

We thank Roy Golsteyn for the gift of the PLK1 plasmid, Olivera Grubisha for critical reading of the manuscript, Robert Weil, Jesus Prieto, Damien Arnoult and Erich Nigg for helpful discussions. This work was supported in part by grants to E.F.M. from a Research Transversal Program (#186) from the Pasteur Institute and by the Agence Nationale pour la Recherche contre le SIDA (ANRS). D.V. was supported by fellowships from ANRS and Pasteur Institute. M.V. was supported by a fellowship in J.H's lab and the Fondation pour la Recherche Medicale (FRM). M.A. was supported by a fellowship from the International network of the Pasteur Institute. The authors declare no conflict of interest.

The abbreviations used are: IFN, Interferon; MAVS, Mitochondrial Anti Viral Signaling; LGP2, "Laboratory of Genetics and Physiology 2" RNA helicase; IPS-1, Interferon promoter stimulator 1; VISA, Virus-induced Signaling Adaptor; Cardif, CARD adaptor inducing IFN-β; CARD, Caspase Activation and Recruitment Domain; FADD, Fas associated protein via Death Domain; RIP, Receptor interacting protein; TNF, Tumor Necrosis Factor; TRAF, Tumor Necrosis Factor Receptor associated factor; TANK, TRAF family member-

associated NF- κ B activator; TBK1, TANK binding kinase 1; IKK ϵ , I κ B kinase epsilon; NF- κ B, Nuclear Factor- κ B; I κ B α (Inhibitor of κ B) α ; IKK, I κ B (Inhibitor of κ B) Kinase; IRF3, Interferon Regulatory Factor-3; IL-8, Interleukin-8; ISG56, Interferon Stimulated Gene 56; ssRNA, single stranded RNA; dsRNA, double stranded RNA; Poly(I)-poly (C), Polyinosinic-polycytidylic acid; siRNA, silencing RNA; RSV, Rous Sarcoma Virus; SIV, Simian Immunodeficiency Virus; VSV, Vesicular Stomatitis Virus; AMV, Avian Myeloblastosis Virus; CMV, cytomegalovirus; PBS, Phosphate Buffered Saline; FBS, fetal Bovine Serum; Gal4, Galactosidase transcription factor; DB, DNA Binding domain; AD, Activation Domain; SEM, Standard Error of the Mean.

FIGURE LEGENDS

Fig 1. Interaction of PLK1 with MAVS

A-HEK 293T cells were transfected with Gal4-luc and pCMV-Renilla reporter plasmids, together with an empty vector, pM-PLK1-PBD, containing the DNA-binding domain of Gal4 fused in frame with the Polo-box domain of PLK1, pVP16-MAVS, containing the full length sequence of MAVS fused in frame with the transactivator VP16, or both pM-PLK1-PBD and pVP16-MAVS. Firefly Gal4-luciferase activity was measured the day after and standardized to the *Renilla* luciferase activity.

B- HEK 293T cells were transfected with pFLAG-PLK1 or pFLAG-PLK1-PBD together with either pcDNA3.1(+) (-) or pMyc-MAVS. 24 h after transfection, cells lysates (buffer B) were subjected to immunoprecipitation (IP) using c-Myc antibodies. The presence of PLK1 (FL), PLK1-PBD (PBD) or MAVS in the immunocomplexes was revealed by immunoblot using anti-FLAG or anti-Myc antibodies. Expression of PLK1, PLK1-PBD and MAVS in total cell extracts was controlled with anti-FLAG or anti-Myc antibodies.

C-HEK 293T and Huh-7 cells were plated at 60% of confluency and incubated after 24 hrs in presence of 1µg/ml Aphidicolin. After 14 hrs of incubation, the medium was removed, the cells washed three times in complete medium and cell extracts were prepared at the indicated times. Expression of endogenous PLK1, MAVS and actin was analyzed by immunoblot using antibodies directed against each of these proteins.

D-HEK 293T or MCF7 cells were treated or not with 50 ng/ml Nocodazole for 20 h. In the case of HEK 293T, cells were also transfected with 3 µg of poly(I)-poly(C) 4 hours before extraction. Cell lysates (Buffer A) were immunoprecipitated with control IgG or anti-MAVS antibodies. The presence of MAVS and PLK1 in the immunoprecipitates and in the total extracts was analyzed by immunoblot using specific antibodies.

Fig 2. PLK1-PBD interacts with two domains of MAVS.

A- HEK 293T cells were transfected with pcDNA3.1(+) (-) or pMyc-MAVS (WT) together with pFLAG-PLK1-PBD either wild type (WT), or mutant (PBD M538/540 or PBD M 414/538/540). 24 hrs after transfection, cells lysates (buffer B) were immunoprecipitated (IP) with anti-c-Myc antibodies. The presence of the PLK1-PBD constructs and MAVS in the immunocomplexes and of PLK1-PBD in total cell extracts was revealed by immunoblot using anti-FLAG or anti-c-Myc antibodies.

B- HEK 293T cells were transfected with pFLAG-PLK1-PBD or pFLAG-PLK1-PBD M 414/538/540 in presence of pcDNA3.1(+) (-) or different pMyc-MAVS constructs as indicated. 24 hrs after transfection, the cell lysates (buffer B) were immunoprecipitated (IP) with anti-c-Myc antibody. The presence of PLK1-PBD or PLK1-PBD M 414/538/540 and MAVS constructs in the immunocomplexes and of PLK1-PBD in total cell extracts was revealed by immunoblot using anti-FLAG and anti-c-Myc antibodies.

C- Schematic representation of the results shown in B. In MAVS, the region deliminating the CARD like domain (CLD) is 1-77, the proline rich region (PRO) is 103-173 and the transmembrane domain (TM) is 514-535. PBD M stands for PLK1-PBD M 414/538/540.

Fig 3. Phosphorylation requirement for binding of PLK1 to MAVS.

HEK 293T cells were transfected with pFLAG-PLK1-PBD (left panel) or pFLAG-PLK1 (right panel) together with one of the following plasmids: pcDNA3.1(+) (-), pMyc-MAVS (FL), pMyc-MAVS 1-360 or pMyc-MAVS 364-540. 24hr after transfection, cells were lysed in buffer B, treated or not with $5U/\mu g$ of λ phosphatase, and submitted to immunoprecipitation (IP) with anti-c-Myc antibodies. The presence of PLK1-PBD, PLK1 and MAVS in the immunocomplexes and of PLK1 in the total cell extracts was revealed by immunoblot using anti-FLAG and anti-MAVS antibodies.

Fig 4. Requirement of MAVS S233 and T234 for its specific binding with PLK1-PBD.

A- HEK 293T cells were transfected with pFLAG-PLK1-PBD in the presence of pMyc-MAVS, either full length (FL) or its fragments 156-540 or 1-513, in which the sequence was either unmodified (-) or carrying the mutations ST233/234A or SS257/258AA (+).

B- HEK 293T cells were transfected with pFLAG-PLK1-PBD in the presence of pMyc-MAVS, either full length (FL) or deleted of its transmembrane domain (1-513), in which the sequence was either unmodified (WT) or carrying the mutations T234A, T234D or T234E. 24 hrs after transfection, cells lysates from experiments A and B (buffer B) were immunoprecipitated with anti-Myc antibodies. The presence of PLK1-PBD and of the MAVS constructs in the immunocomplexes and of PLK1-PBD in the total cell extracts was revealed by immunoblot using anti-FLAG or anti-Myc antibodies.

C- HEK 293T cells were transfected with pMyc-MAVS full length (FL) or its fragments 1-360 and 364-540 in presence of pcDNA3.1(+) (1), pFLAG-IKK ϵ (2), or pFLAG-PLK1 (3). Six hours after transfection, the cells were incubated for 10 hours in the presence of 1 mCi [32P] orthophosphoric acid and 20 μ M MG132. The cells lysates (buffer A) were immunoprecipitated with anti-c-Myc antibodies. The presence of MAVS constructs in the immunoprecipitates was first controlled by immunoblot using anti-MAVS antibodies, after which the membrane was exposed against an intensifying screen to reveal the [32P] labelled proteins through scanning on a phosphorimager (STORM). The membrane was then analyzed by immunoblot for the expression of PLK1 or IKK ϵ using anti-FLAG antibodies. Expression of IKK ϵ or PLK1 in the total cell extracts was controlled by immunoblots using anti-FLAG antibodies.

D- HEK 293T cells were transfected with 1, 2 or 4 µg of pDEST GST-MAVS 1-360 or pDEST GST-MAVS 1-360T234A and labelled with 1 mCi [32P] orthophosphoric acid as above. The cells were lysed in buffer B minus glycerol and the GST-MAVS constructs were purified on Glutathion-sepharose. The presence of MAVS constructs and phosphoMAVS was revealed as above. The quantification of the phosphorylated bands versus the bands on the immunoblot was calculated using the ImageJ software (http://rsb.info.nih.gov).

Fig 5. PLK1 inhibits the MAVS-mediated IFN induction.

A- HEK 293T cells were transfected with pMyc-MAVS (10 ng) alone or in presence of pMyc-PLK1 (50 ng and 100 ng) and in the presence (top) or in the absence (middle and bottom) of IFN- β -pGL2 and pRSV- β gal. pMyc-PLK1 was also expressed individually. 24 hr after transfection, luciferase activity was measured and normalized against the β galactosidase activity (top panel). Expression levels of endogenous ISG56 (middle panel), and IL-8 (lower panel) were measured by RT-qPCR and normalized against endogenous GAPDH levels. Error bars represent the mean standard deviation for triplicates.

B- HEK 293T cells were transfected with 400 ng of an empty vector or pMyc-PLK1 in the presence (left) or in the absence (right) of IFN β -pGL2 and pRSV- β gal. 24 hr after transfection, cells were either mock infected or infected with 20 HAU/ml of Sendaï virus. The stimulation of the IFN β reporter plasmid or induction of the IFN β endogenous gene were measured 18h after infection, either by luciferase activity (left) or by RT-qPCR (right). Relative expression levels of IFN β versus GAPDH is shown. Data are representative of two experiments run in triplicate.

C- Top: HEK 293T cells were transfected with pMyc-MAVS (10 ng), either WT or with the mutation T234A, the deletion $\Delta 364$ -470 or both (T234A $\Delta 364$ -470) in presence of 50 ng and 100 ng of pPLK1(top) or pPLK1-PBD (bottom) and in the presence of IFN- β -pGL2 and pRSV- β gal. 24 hr after transfection, luciferase activity was measured and normalized against the β galactosidase activity. The experiment was done in triplicate.

Bottom: HEK 293T cells were transfected with pFLAG-PLK1-FL or pFLAG-PLK1-PBD in the presence of pMyc-MAVS, either full length (1-540) or deleted of the 364-470 domain (Δ364-470), in which the sequence was either unmodified (WT) or with the mutation T234A. 24 hrs after transfection, the cells were lysates (buffer B) were immunoprecipitated with anti-Myc antibodies. The presence of the PLK1 and MAVS constructs in the immunoprecipitates and of the PLK1 constructs in the total cell extracts was revealed by immunoblot using anti-FLAG and anti-Myc antibodies.

D-HEK 293T cells were first transfected with 50 nM of Control (scrambled) or PLK1 siRNA and, after 24 hrs, with IFN- β -pGL2 and pRSV- β gal in presence of pMyc-MAVS (100, 200 or 400 ng). Luciferase activity was analyzed 24 h after the second transfection and normalized to the β galactosidase activity. Error bars represent the mean standard deviation for triplicates and the p values were calculated according to the Student's t test. Cells lysates were analyzed by immunoblot using PLK1 and actin antibodies.

E- HEK 293T cells were transfected with 50 nM of Control or PLK1 siRNA and, after 24 hrs, with IFN- β -pGL2/pRSV- β gal and pRIG-I (400 ng). The cells were then infected with Sendaï virus (20 HAU/ml). After 6 hrs, Luciferase activity was measured and normalized to the β galactosidase activity.

Fig 6. PLK1 inhibits binding of TRAF3 to MAVS.

A. *left* HEK 293T cells were transfected with pFLAG-TRAF3, pMyc-MAVS and increasing amounts of pEGFP-PLK1-PBD. 24 hr after transfection, cell lysates (buffer B) were immunoprecipitated (IP) using c-Myc antibodies. The presence of TRAF3 (upper panel), MAVS and PLK1-PBD (middle panels) in the immunocomplexes was revealed by immunoblot using anti-FLAG, anti-c-Myc or anti-PLK1 antibodies. Expression of TRAF3 was controlled in the total cell extracts using anti-FLAG antibodies (lower panel).

A.Right. HEK 293T cells were transfected with pV5-IKKε, pMyc-MAVS and increasing amounts of pFLAG-PLK1-PBD. After 24 hr, Myc-MAVS was immunoprecipitated as in A. The presence of IKKε (upper panel), MAVS and PLK1-PBD (middle panels) in the immunocomplexes was revealed by immunoblot using anti-V5, anti-c-Myc or anti- FLAG antibodies. IKKε was measured in total cell extracts using anti-V5 antibodies (lower panel).


B. HEK 293T cells were transfected with pFLAG-TRAF3 together with pMyc-MAVS 1-360 or pMyc-MAVS 364-540 and increasing amounts of pEGFP-PLK1-PBD. After 24 hr, Myc-MAVS was immunoprecipitated as in A. The presence of TRAF3 (upper panel), MAVS and PLK1-PBD (middle panels) in the immunocomplexes was revealed by immunoblot using anti-FLAG, anti-c-Myc or anti-PLK1 antibodies. TRAF3 was measured in total cell extracts using anti-FLAG antibodies (lower panel).


Fig 7. PLK1 participates in the inhibition of IFN induction during treatment with nocodazole

HEK 293T cells were first transfected with 50 nM of Control or PLK1 siRNA and, after 24 hrs, with IFN-β-pGL2/pRSV-βgal in the absence or presence of 400 ng of pRIG-I. 8 hrs after transfection, the cells were submitted to nocodazole treatment (50ng/ml) for 20 hrs. 6 hours before the end of treatment, cells were transfected with 100 ng/ml of poly(I)-poly(C). Luciferase activity was analyzed 6 h after the second transfection and normalized to the βgalactosidase activity. Error bars represent the mean standard deviation for triplicates. Cells lysates were analyzed by immunoblot using PLK1 antibodies.

Fig 8- Model of interaction of PLK1 with MAVS

PLK1 interacts with the STP motif present in the MAVS 180-280 domain through its phosphopeptide docking site contained within its Polo-Box. This interaction is dependent on the phosphorylation of MAVS T234. The PLK1 Polo-Box interacts also with a region of MAVS at its C-terminal domain but does not use its phosphopeptide docking site for this. The latter interaction is responsible for the inhibition of the recruitment of TRAF3 to MAVS and for the inhibition of IFN induction.





MAVS constructs	PBD	PBD M
CLD PRO		
540	-	+/-
156 540		
364 540		-1-
470 540		
157	3==8	
180		
230		
280		
330		
508		-
156 513	+	
180 513	-	
230 513		
280 513		
330 513		

binding



